TGFB1 and systemic sclerosis: Precisely, BM-MSC-EV treatment led to a significant reduction in TGF-β1-positive cells, α-SMA-positive myofibroblasts, mast cells, infiltrating macrophages, and lymphocytes in the skin of SSc mice.